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Abstract
Objective
To identify and characterize myeloid cell populations within the CSF of patients with MS and
anti-myelin oligodendrocyte glycoprotein (MOG) disorder by high-resolution single-cell gene
expression analysis.
Methods
Single-cell RNA sequencing (scRNA-seq) was used to proﬁle individual cells of CSF and blood
from 2 subjects with relapsing-remitting MS (RRMS) and one with anti-MOG disorder.
Publicly available scRNA-seq data from the blood and CSF of 2 subjects with HIV were also
analyzed. An informatics pipeline was used to cluster cell populations by transcriptomic proﬁling. Based on gene expression by CSF myeloid cells, a ﬂow cytometry panel was devised to
examine myeloid cell populations from the CSF of 11 additional subjects, including individuals
with RRMS, anti-MOG disorder, and control subjects without inﬂammatory demyelination.
Results
Common myeloid populations were identiﬁed within the CSF of subjects with RRMS, antiMOG disorder, and HIV. These included monocytes, conventional and plasmacytoid dendritic
cells, and cells with a transcriptomic signature matching microglia. Microglia could be discriminated from other myeloid cell populations in the CSF by ﬂow cytometry.
Conclusions
High-resolution single-cell gene expression analysis clearly distinguishes distinct myeloid cell
types present within the CSF of subjects with neuroinﬂammation. A population of microglia
exists within the human CSF, which is detectable by surface protein expression. The function of
these cells during immunity and disease requires further investigation.
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Glossary
AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; BAM = border-associated macrophage; CCA = canonical
correlation analysis; cDC = conventional DC; DAM = disease-associated microglia; DC = dendritic cell; HC = healthy control;
HLA-DR = human leukocyte antigen DR; IIH = idiopathic intracranial hypertension; MOG = myelin oligodendrocyte
glycoprotein; NMO = neuromyelitis optica; PBMC = peripheral blood mononuclear cell; PCA = principal component analysis;
pDC = plasmacytoid DC; RRMS = relapsing-remitting MS; scRNA-seq = single-cell RNA sequencing; UMAP = Uniform
Manifold Approximation and Projection.

CSF evaluation is used to aid in the diagnosis and diﬀerentiation of CNS disorders. In inﬂammatory CNS diseases, the CSF
is typically used to assess the immunopathophysiologic processes because biopsy of CNS tissue carries signiﬁcant potential
for harm.1 However, relatively few cells are obtained from CSF,
usually on the order of 1–5 cells/μL. Recent reﬁnements in
next-generation sequencing have enabled the eﬃcient determination of individual cell gene expression within biospecimens with relatively sparse cell populations, such as the
CSF. Patterns identiﬁed using single-cell RNA sequencing
(scRNA-seq) can uncover distinct cell types present at low
levels within cellular communities and tissues.2 scRNA-seq was
used to assess inﬂammatory changes within the CSF of subjects
with HIV infection, identifying the presence of a “microgliallike” cell,3 and more recently to explore the clonal expansion of
CSF lymphocytes in MS-discordant monozygotic twin pairs.4
scRNA-seq has also been used to address the issue of microglial
heterogeneity within the human brain.5–7 In addition, using the
primary animal model of MS, experimental autoimmune encephalomyelitis, scRNA-seq has been used to identify several
populations of myeloid cells, both endogenous to the CNS and
from peripheral blood.8 New methods for characterization of
myeloid populations within the CNS during disease oﬀer the
opportunity to dissect the origin, function, and pathogenicity of
each cell type with much greater resolution than previous
methods.
MS is the most common inﬂammatory demyelinating disease
of the CNS, aﬀecting over 600,000 people in the United
States.9 Anti-myelin oligodendrocyte glycoprotein (MOG)
disorder is a newly described CNS demyelinating disease that
shares clinical and pathologic characteristics with MS.10,11 MS
and anti-MOG disorder appear to be distinct from one another and from aquaporin 4 antibody-positive neuromyelitis
optica (NMO).10,12 We have applied scRNA-seq to examine
the CSF and mononuclear cells of the peripheral blood of
subjects with relapsing-remitting MS (RRMS) and anti-MOG
disorder. Individual spinal ﬂuid samples from 2 subjects with
RRMS and 1 subject with anti-MOG disorder were analyzed
by using scRNA-seq. In all 3 subjects, we uncovered CSF
populations of immune cells including microglial cells, monocytes, and dendritic cells (DCs) based on gene expression.
Using CSF and blood from 7 additional subjects with RRMS,
another subject with anti-MOG disorder, and 3 control subjects, we designed and tested a ﬂow cytometry strategy that
conﬁrmed the presence in CSF of these cell types.
2

Methods
Subjects
Eleven subjects with inﬂammatory demyelinating disease (9
with RRMS and 2 with anti-MOG disorder) and 3 control
subjects (1 with amyotrophic lateral sclerosis [ALS], 1 with
idiopathic intracranial hypertension [IIH], and 1 healthy control
[HC]) were recruited for a study to assess the characteristics of
CSF and blood cells (table). The institutional review board of
Washington University in St. Louis approved study protocols,
and each subject provided informed consent. Nine subjects had
RRMS based on the current diagnostic criteria.13 Two additional subjects were diagnosed with anti-MOG disorder: one
presented with optic neuritis and the other with partial transverse myelitis. Anti-MOG disorder was diagnosed based on the
6-month sustained positive cell-based assays for MOG IgG1
antibody, absence of antibodies to aquaporin 4 (NMO-IgG),
and absence of CSF-restricted oligoclonal bands.11
To prevent alterations because of disease-modifying therapies, we
selected subjects either on no therapy or remote from therapy.
Seven subjects with RRMS were naive to therapy, including corticosteroids. Of the remaining 2 subjects with RRMS, 1 (subject 7)
had received ﬁngolimod, stopping 9 months before CSF testing,
and the other (subject 10) was treated with glatiramer acetate for 5
months and had received IV steroids 2 months before CSF analysis. The subject with transverse myelitis due to anti-MOG disorder
(subject 8) had received mycophenolate and then azathioprine but
had discontinued these 6 months before CSF analysis and had
received a course of corticosteroids 4 months before CSF examination. Subject 1 with anti-MOG disorder had received no treatment before the examination of CSF. Control specimens were
obtained from a subject with IIH who presented with visual disturbances, a patient diagnosed with ALS, and a HC. Each contributed blood and CSF cells for scRNA-seq or ﬂow cytometry
studies (table and ﬁgure e-1, links.lww.com/NXI/A244).
Standard protocol approvals, registrations,
and patient consents
Informed consent was obtained from all participants and
approved by the Human Research Protection Oﬃce of
Washington University in St. Louis.
CSF and peripheral blood mononuclear
cell preparation
CSF was collected in a 50-mL conical tube on ice and
centrifuged for 10 minutes at 400g. Supernatant was removed
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Table Demographic and clinical characteristics of subjects
Subject

Age, y

Sex

Race

Diagnosis

Presentation at onset

Time from symptom
onset to LP

CSF OCB

Analysis

1

56

F

Caucasian

Anti-MOG disorder

ON OD and paresthesias

8 mo

0

scRNA-seq

2

38

F

Caucasian

RRMS

ON OD

6 wk

3

scRNA-seq

3

53

F

Caucasian

RRMS

Paresthesias

3y

13

Flow cytometry

4

23

F

Caucasian

RRMS

ON OD

4 mo

7

Flow cytometry

5

34

F

Caucasian

RRMS

ON OD

2y

11

scRNA-seq

6

40

F

Caucasian

RRMS

Paresthesias and tremor

15 mo

5

Flow cytometry

7

41

F

Caucasian

RRMS

ON OS

12 y

9

Flow cytometry

8

22

M

Caucasian

Anti-MOG disorder

Paresthesias and leg weakness

2y

0

Flow cytometry

9

45

M

Caucasian

RRMS

Lhermitte sign

6 mo

7

Flow cytometry

10

38

F

Caucasian

RRMS

ON OS

6 mo

10

Flow cytometry

11

38

F

Caucasian

IIH

TVO

1y

0

Flow cytometry

12

70

M

Caucasian

ALS

Weakness

4y

N/D

Flow cytometry

13

45

M

Caucasian

HC

N/A

N/A

N/D

Flow cytometry

14

40

M

Caucasian

RRMS

Right-sided weakness

3 mo

4

Flow cytometry

Abbreviations: ALS = amyotrophic lateral sclerosis; HC = healthy control; IIH = idiopathic intracranial hypertension; OD = oculus dextra (right eye); ON = optic
neuritis; OS = oculus sinistra (left eye); LP = lumbar puncture with CSF analysis; MOG = myelin oligodendrocyte glycoprotein; N/A = not applicable; N/D = not
done; OCB = oligoclonal band; RRMS = relapsing-remitting MS; scRNA-seq = single-cell RNA sequencing; TVO = transient visual obscuration.

without disrupting the cell pellet, which was resuspended in
400 μL of PBS containing 0.04% bovine serum albumin. The
CSF cells were counted with a hemocytometer and resuspended in a volume of PBS/0.04% bovine serum albumin to
achieve a cell concentration of 700–1,000 cells/μL for scRNAseq. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density centrifugation and then processed
alongside CSF cells for scRNA-seq or ﬂow cytometry.
Flow cytometry
Flow cytometry analysis was performed using antihuman
antibodies to BDCA-2 (clone 201A; BioLegend, San Diego,
CA), CD33 (clone P67.6; BioLegend), CD14 (clone 61D3;
eBioscience, San Diego, CA), Lyve-1 (clone 537028; R&D
Systems, Minneapolis, MN), CD3 (clone SK7; BioLegend),
CD19 (clone HIB19; eBioscience), CD16 (clone B73.1;
BioLegend), CD1c (clone L161; BioLegend), Lox-1 (clone
15C4; BioLegend), and human leukocyte antigen DR (HLADR) (clone Immu-357; Beckman Coulter, Brea, CA). One
million PBMCs and between 2 × 104 and 40 × 104 CSF cells
were incubated with human-Fc block (BD Biosciences, San
Jose, CA) for 10 minutes at RT and then with antibodies for
20 minutes at 4°C. Subsequently, the samples were washed
with PBS + 2% FBS (ﬂow buﬀer) for 59, spun at 500g, and
resuspended in 200 μL of ﬂow buﬀer. The samples were run
on a Gallios ﬂow cytometer (Beckman Coulter Life Sciences)
on the same day of the collection. The cells were analyzed
using FlowJo software (Tree Star, Ashland, OR).
Neurology.org/NN

RNA sequencing and analysis
On the day of cell collection using fresh cells, droplet-based 39
(for anti-MOG disorder subject 1) and 59 (for subjects 2 and
5 with RRMS) libraries were prepared using Chromium
Single Cell 39 v2 or 59 Reagent Kits according to the manufacturer’s protocol from 10× Genomics. The generated
scRNA libraries were sequenced using an Illumina HiSeq4000
or Novaseq sequencer. Cell Ranger Single-Cell Software 2.2
was used to perform sample demultiplexing, barcode processing, and single-cell 39 and 59 counting. Afterward, fastq
ﬁles for each sample were processed with a cellranger count,
which was used to align the samples to GRCh38 genome,
ﬁlter, and quantify reads. For each sample, the recovered-cells
parameter was speciﬁed as 10,000 cells that we expected to
recover for each individual library.
To reanalyze scRNA-seq data performed with SeqWell publicly
available from GSE117397, we downloaded count tables from 2
subjects with HIV for whom both CSF and blood samples were
available from GEO DataSets (GSM3293822, HIV1_Bld;
GSM3293823, HIV1_CSF; GSM3293824, HIV2_Bld;
GSM3293825, HIV2_CSF). To combine data from all samples
together, we used the canonical correlation analysis (CCA) algorithm from Seurat 3.14 Before applying CCA, we removed
cells from the 39 and 59 data sets that contain more than 10% of
mitochondrial RNA. Cells from SeqWell data sets with less than
20% of RNA from mitochondrial genes and more than 500 but
less than 2,500 expressed genes were considered viable cells.
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After CCA data were scaled, principal component analysis
(PCA) was performed with RunPCA function. A Uniform
Manifold Approximation and Projection (UMAP) dimensionality reduction was performed on the scaled matrix
using the ﬁrst 20 PCA components to obtain a 2-dimensional
representation of the cell states.15 For clustering, we used
FindNeighbours and FindClusters functions on 20 PCA
components with a resolution of 0.5. FindAllMarkers function
was used to characterize clusters. For heatmap representation,
the mean expression of markers inside each cluster was used.
Heatmaps were built with Phantasus software (artyomovlab.
wustl.edu/phantasus/).
Data availability
Anonymized scRNA-seq is available to qualiﬁed investigators
at synapse.org (syn21904732).

Results
Discrete immune cell populations can be
identified in the CSF and blood of subjects with
neuroinflammatory diseases using scRNA-seq
To explore the extent, diversity, and phenotype of leukocyte
inﬁltration into the CNS compartment during CNS demyelination, we performed scRNA-seq of CSF cells and
PBMCs from 1 subject with anti-MOG disorder (subject 1)
and 2 subjects with RRMS (subjects 2 and 5). During the
course of our data collection, scRNA-seq of immune cells
isolated from the blood and CSF of subjects with HIV was
reported.3 Given the small number of data sets on CSF,
a diﬃculty to access tissue, we sought to optimally identify
populations of immune cells reﬂective of neuroinﬂammation
using a recently described computational method, CCA, that
allows integration across diﬀerent scRNA-seq technologies.14
Applying this method, data from a total of 23,363 PBMCs and
14,179 CSF cells were combined and visualized using the
UMAP technique15 and unsupervised clustering.16,17
Twenty clusters representing distinct cell populations were
identiﬁed (ﬁgure 1A). We used the characteristic marker gene
expression to assign cellular identities to each cluster (ﬁgure
1B). Several distinct lymphoid cell clusters, including CD8+
T cells, CD4+ T cells, γδ T cells, NK cells, and B cells, could be
discriminated in both PBMCs and CSF. Myeloid populations
were also identiﬁed, including microglia, CD14+ and CD16+
monocytes, and 2 distinct groups of DCs—plasmacytoid
(pDCs) and conventional (cDCs). Examining each subject
individually, there were no meaningful disparities in cell clusters
between the subjects (ﬁgure e-2, links.lww.com/NXI/A244).
We also compared the proportional abundance of speciﬁc cell
clusters within either the CSF or blood (ﬁgure 1C). We
identiﬁed a cluster of cells that exhibited features of cell stress,
including expression of the mitochondrial genes MTRNR2L8
and MTRNRL12, which are indicative of low quality or dying
cells (labeled “Dead” in ﬁgure 1).7 These dead cells, as well as
4

red blood cells and platelets, were found almost solely within
the blood. Similarly, we observed one population of NK cells
(NK_1) that was exclusively present in the blood. This population shows a gene expression proﬁle matching the recently
deﬁned blood NK1 cells, which align with previously described
CD56dim NK cells (ﬁgure e-3, links.lww.com/NXI/A244).18
Among the T and B cell clusters, several exist in higher
abundance in the blood (naive CD8, CD8_2, CD8_3, naive
CD4, γδ T cells, and B_cells_1). CD14+ and CD16+ monocytes were more prevalent in blood than CSF, with the latter
being entirely absent from the CSF. cDCs were a smaller
fraction among PBMC relative to CSF cells, whereas pDCs
were found in both compartments in similar proportions.
Microglia were exclusively found in the CSF. Given the
complexity of cells with myeloid characteristics in neuroinﬂammatory diseases and the historic diﬃculty of studying
these cells in CSF by conventional methods because of limited
cell numbers, we dedicated subsequent analyses of our data to
CSF myeloid cell populations.
CSF microglia and other myeloid cell types
in neuroinflammation
Analyzing the genes expressed by the cluster of CSF cells that
we term microglia revealed high expression of genes from the
microglial homeostatic gene signature, including CX3CR1,
CSF1R, SLC2A5, MARCKS, and P2RY13 (ﬁgure 2A).7,19,20
Recent scRNA-seq analyses of human brain microglia have
deﬁned heterogeneity among microglia.6,7 Sankowski et al.7
deﬁned 8 clusters of human brain microglia (termed C1–C3,
C5–C9) with diﬀerential gene expression among these clusters. Expression of these microglia cluster-speciﬁc genes
across the myeloid cell populations from our scRNA-seq
composite data set was next examined. Many of these genes
were found to be strikingly microglia-speciﬁc, including
APOC1, APOE, LYVE1, TREM2, C1QB, GPR34, OLR1, and
C3 (ﬁgure 2B). Sankowski et al. also created a classiﬁer tool to
discriminate microglial clusters, which they successfully applied to publicly available scRNA-seq data sets of brain
microglia. When we applied this classiﬁer to the 394 CSF cells
in our data set that were grouped as microglia, 88% of these
were classiﬁed as belonging to C6, with 10% belonging to C7.
C6 and C7 were characterized by Sankowski et al. as having
high expression of genes in the Gene Ontology pathway
0048002 (“antigen processing and presentation of peptide
antigen”). In sum, these data strongly support our conclusion
that the myeloid cell populations we ﬁnd exclusively in the
CSF are microglial cells and suggest that they may be involved
in antigen presentation.
Two previous studies using scRNA-seq to classify CSF
immune cells, each identiﬁed a discrete cell population
that was categorized as either “microglia-like” cells3 or
“monocytes.”4 Each study produced a list of genes that
discriminated these diﬀerently named clusters from other
CSF immune cells. When we visualized these gene sets
among the clusters of CSF cells in our composite data set,
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Figure 1 scRNA-seq characterization of leukocytes from MS, anti-MOG disorder, and HIV

(A) UMAP of immune cell clusters from the blood (top) and CSF (bottom) of all subjects merged. (B) Characteristic marker gene expression assigned to each
cluster displayed by UMAP. (C) Proportional abundance of 20 cell clusters within the blood (purple) and CSF (yellow). Y axis represents the percentage of all
cells. cDC = conventional DC; PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC; RBC = red blood cell; Tgd = γδ T cells; UMAP = Uniform
Manifold Approximation and Projection.

which includes a reanalysis of the cells from 2 subjects included in the work of Farhadian et al., we found markedly
enriched expression in the cluster that we term microglia
(ﬁgure 2C). With this, we mean that all 3 studies are in fact
referring to the same subset of CSF cells, and given their
expression of core microglial genes, we prefer to classify
these as microglia.
Other myeloid populations could also be distinctly classiﬁed by
their transcriptional proﬁles. Figure 3 is a heatmap of the expression of 10 genes per cell type, which discriminated each
myeloid population. Some of these genes were known to discriminate myeloid cell types, yet others are new and could be
revealing diﬀerent classiﬁers. Notably, expression of major
Neurology.org/NN

histocompatibility complex class II genes was higher in CSF
cDCs than blood cDCs, possibly indicating a compartmental
inﬂuence on the antigen presentation function of these cells.
These transcriptomic data establish the presence of one
monocyte subset, 2 types of DCs, and microglia within the CSF
during neuroinﬂammation.
Flow cytometric characterization of CSF cells
validates scRNA-seq identification of microglia
and myeloid cell types
We sought to create a ﬂow cytometric-based strategy for the
quantiﬁcation of various CSF myeloid cell types, including
microglia, using commercially available antibodies speciﬁc for
surface markers identiﬁed by our gene expression studies
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(ﬁgure e-4, links.lww.com/NXI/A244) and the literature.21
PBMCs and CSF cells were stained for CD3 and CD19 to
gate out T and B cells. Within the remaining cells in both CSF
and blood, pDCs were identiﬁed as being HLA-DR+ and
BDCA-2+ (encoded by CLEC4C), whereas cDCs were
identiﬁed as HLA-DR+BDCA-2−CD1c+ cells (ﬁgure 4A). In
the CSF, non-DCs could be seen to resolve as 2 distinct cell
types based on the HLA-DR and CD33 levels. PBMCs only
contained HLA-DRmidCD33high cells, which were deﬁned as
monocytes. The CSF additionally contained a population of
HLA-DRhighCD33mid cells, which we interpreted as microglia,
further conﬁrmed by their expression of Lyve-1 and Lox-1
(encoded by OLR1). CSF from subjects with other neurologic
conditions (anti-MOG disorder, ALS, and IIH) and a HC
subject also contained similarly staining populations of pDCs,
cDCs, monocytes, and microglia (ﬁgure 4B). The staining
intensity of HLA-DR, CD33, Lyve-1, and Lox-1 discriminated
CD14+ monocytes from microglia in the CSF of all subjects
(ﬁgure 4C). Overall, ﬂow cytometric characterization of myeloid cells demonstrated the protein expression of various
microglial genes identiﬁed by transcriptomic proﬁling, conﬁrmed the presence of microglia within the CSF, and oﬀered
a ready means for identifying this cell type.

Discussion
We performed scRNA-seq to identify the cell types present
within the CSF of 2 subjects with RRMS and 1 person with
anti-MOG disorder, with comparative analysis to paired
PBMCs. These and subsequent subjects were not taking
disease-modifying therapies or corticosteroids. Subsequently,
we integrated publicly available data on 2 subjects with HIV
on whom scRNA-seq was performed on paired PBMCs and
CSF immune cells. We then focused on CSF myeloid cell
types because less work has been carried out to characterize
these populations in part because of their lower abundance.
We found that (1) scRNA-seq identiﬁes a diverse set of myeloid cell types within the CSF, including microglia; (2) ﬂow
cytometry is a feasible technique for the discrimination of
these populations of CSF myeloid cells; and (3) scRNA-seq
data can be integrated across technologies to allow for optimal
discrimination of cell populations.
Because the data sets we analyzed were derived from diﬀerent
technologies, we used a recently described technique, CCA, to
integrate scRNA-seq data sets. This allowed for an increased
number of cells used in the analysis, facilitating the optimal
discrimination of cell clusters. All CSF samples in the combined
analysis contained cells within each cluster, suggesting that
among the diseases examined herein, a common set of leukocytes inhabit this critical immune space within the CNS. One
limitation of CCA involves the exclusion of some genes from
downstream analysis. Nevertheless, in our case, 2,000 genes
were still available for use in our assessment of PBMCs and
CSF cells from 5 individuals. Our results demonstrate the
feasibility of using CCA to integrate the growing number of
6

scRNA-seq data sets that will continue to be made publicly
available using diﬀerent platforms.
Our scRNA-seq analysis identiﬁed microglia in human CSF
with a gene expression pattern overwhelmingly similar to
that described for parenchymal microglia.7,19,22,23 We used
genes from a recent study describing the transcriptional
proﬁle of human tissue-resident microglia as a comparison
for the CSF microglia identiﬁed in our subjects.7 The top
genes identiﬁed in tissue-resident microglia were also highly
abundant in our CSF microglia populations (ﬁgure 2).
Owing to their low abundance in the CSF, this subset of cells
has apparently been overlooked in most previous CSF
studies using less powerful techniques. One previous report
using a diﬀerent scRNA-seq platform, SeqWell, also identiﬁed this population of cells in human CSF and termed them
“microglia-like.”3 Our reanalysis of the published data from
the latter study conﬁrmed the presence of cells expressing
hallmark microglial genes and lacking expression of genes
that identify other myeloid cell types. A more recently
published study involving patients with MS also identiﬁed
several distinct myeloid cell types within the CSF.24 Based
on the analysis of our data, we believe this group used the
term “Mono2” in reference to a population encompassing
CSF microglia. Indeed, they describe a subset of monocytes
that expressed microglial-associated genes, including
TREM2, TMEM119, and GPR34, and concluded that these
cells share features with both border-associated macrophages (BAMs), which have been ascribed immunoregulatory functions within the CNS,22 and homeostatic microglia.
In the future, it will be important to devise nomenclature
which prudently encompasses the appropriate degree of
segregation among various myeloid cell populations. In
particular, BAMs share substantial transcriptional overlap
with microglia,25 prompting the consideration of how CSF
microglia diﬀer in ontogeny and function from BAMs that
will need to be resolved with further investigation into the
ontogeny and function of each cell type.
Microglia are long-lived, self-replicating, yolk sac-derived
immune cells of the CNS parenchyma involved in CNS
development and neuropathology.26,27 Disruption of the
blood-brain barrier can allow the replacement of microglia by
blood-derived progenitors, with the latter eventually taking on
the near-complete gene expression proﬁle of fetal-derived
microglia.28 Our studies of CSF microglia cannot determine
their ontogeny or how they gained access to the CSF.
Microglia from the CNS parenchyma might traverse the pia
mater or choroid plexus or traﬃc into CSF through perivascular spaces or via lymphatic drainage.29,30 Migration of
parenchymal microglia or blood-derived progenitor cells that
become microglia may occur in response to chemokines,
which is supported by our ﬁnding of chemokine receptors on
these cells, including CCR1, CCR5, CXCR4, and CX3CR1. It
is also possible that a unique microglial subset exists that
develops and permanently resides in the CSF. CSF microglia
also may not be singular in origin.31
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Figure 2 Relative expression of myeloid population-defining genes in neuroinflammation

(A) Expression of canonical microglial genes within the UMAP of CSF immune cell clusters. (B) Heatmap representation of gene expression in blood (purple)
and CSF (yellow) myeloid populations. Gene list derived from Sankowski et al.7 (C) Top genes reported by Farhadian et al.3 as specific for “microglia-like cells”
(top) and Beltran et al.4 as specific for “monocytes” (bottom) displayed in the UMAP of immune cell clusters in the CSF of all subjects. cDC = conventional DC;
PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC; UMAP = Uniform Manifold Approximation and Projection.

Neurology.org/NN
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Figure 3 Discrimination of myeloid cell populations in neuroinflammation by gene expression

Heatmap of 10 genes that discriminate myeloid cell types within the blood (purple) and CSF (yellow). Columns represent individual subjects. cDC = conventional DC; PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC.

The source of CSF microglia may have functionally relevant
implications. Microglia are known to be critical modulators of
CNS developmental processes, such as synaptic pruning.32,33
8

Recent data reveal the subsets of microglia with distinct
functions. In the scRNA-seq analysis of rodent CNS, BAMs
and other myeloid populations have been identiﬁed within
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Figure 4 Flow cytometric identification of microglia and myeloid cells within the blood and CSF

(A and B) Plots were obtained by gating on CD3−CD19− singlets. HLA-DR+BDCA-2hi cells represent pDCs. cDCs are represented as HLA-DR+BDCA-2−CD1chi. Red
gates in the third column represent microglia, whereas blue gates represent monocytes. The fourth column shows HLA-DR and Lyve-1 staining of microglia
(red) and monocytes (blue). The fifth column shows HLA-DR and Lox-1 staining of microglia (red) and monocytes (blue). (A) Flow cytometry on CSF and blood
samples from a subject with RRMS. (B) Flow cytometry on CSF from subjects with anti-MOG disorder (anti-MOG), ALS, IIH, and a healthy control. (C) Mean
fluorescence intensity (MFI) of HLA-DR, CD33, Lyve-1, and Lox-1 of CSF monocytes and microglia from subjects. Each pair of connected circles represents one
CSF sample. Statistical significance was determined using a paired Student t test. ALS = amyotrophic lateral sclerosis; cDC = conventional DC; IIH = idiopathic
intracranial hypertension; MOG = myelin oligodendrocyte glycoprotein; PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC.
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brain, choroid plexus, and leptomeningeal tissue at steadystate and in the experimental autoimmune encephalomyelitis
model of MS.8 Studies using animal models for Alzheimer
disease (AD) have identiﬁed a phagocytic subset of microglia
termed “disease-associated microglia” (DAM).23 DAM appear to reduce disease severity in the model and express genes
associated with AD such as Apoe and Trem2. In addition,
homeostatic microglia and a subpopulation transitioning between homeostatic microglia and DAM were identiﬁed in
mouse AD models. Experiments such as these in mice highlight not only the high resolution of CNS myeloid cell subtypes that can be obtained using scRNA-seq but also the
apparent dynamic nature of myeloid populations.
Using a ﬂow cytometric panel with commercially available
reagents, our data demonstrated the protein expression of some
of the microglial genes identiﬁed by RNA and indicate that
microglia range from 0.2% to 5.5% of CSF mononuclear cells.
Overall, the presence of microglia within the CSF was not
disease-dependent or disease-activity dependent because they
were detected in the CSF of a healthy subject as well as in subjects
with noninﬂammatory neurologic diseases (IIH, ALS) and in 2
distinct neuroinﬂammatory diseases (MS and anti-MOG disorder). Comparison of CSF microglial frequencies between diseases could not be performed because of low cell numbers. It is
possible that subtle diﬀerences in the numbers or subtypes of
CSF microglia could reﬂect the state of disease in MS or other
diseases. Neither of the subjects with RRMS nor the subject with
anti-MOG disorder analyzed for our study was undergoing acute
relapse, which may have inﬂuenced the presence or number of
CSF microglia. Our data demonstrate the feasibility of using
standard ﬂow cytometry in the future to address the association of
CSF myeloid populations, including CSF microglia, with the
clinical state of inﬂammatory demyelination within the CNS.
cDCs and pDCs were each identiﬁed in CSF by both scRNAseq and ﬂow cytometry. Previous studies have identiﬁed these
cell types in CSF using lower resolution ﬂow cytometry with
fewer markers for discrimination of these myeloid populations
and have reported an increased number of pDCs in the CSF
during MS relapses.21,34 Recent scRNA-seq analysis examined
DCs and monocytes in human blood, identifying 6 discrete
subsets of blood DCs, including 4 subsets of cDCs, a subset of
classical pDCs, and a new subset termed AXL+SIGLEC6+ (AS)
DCs.35 ScRNA-seq analysis of the samples in our study did not
result in discrete clusters of DC subsets in the blood or CSF,
perhaps owing to their low abundance. A dedicated scRNA-seq
study focused on sorted CSF DCs would likely reveal additional
heterogeneity in these populations. More importantly, our
analyses of diﬀerentially expressed genes between cDCs in the
CSF compared with cDCs in the blood reveal that these populations, although still fundamentally cDCs, may alter some of
their gene expression based on their microenvironment. Interestingly, those genes that most discriminated CSF cDCs were
more highly expressed by CSF microglia, whereas those that
discriminated blood cDCs were more highly expressed by blood
monocytes. These results suggest that environmental signals
10

may result in shared tissue-speciﬁc gene expression patterns
across myeloid cell populations.
Using gene expression-based methods to categorize cell types,
we identiﬁed microglia, monocytes, cDCs, and pDCs within
the CSF. The recognition that microglia are present in CSF
may have important clinical implications. Abnormally functioning microglia are believed to contribute to the pathogenesis
and/or regulation of several diseases, including AD and MS.
Our results indicate that it may be possible to analyze microglial
abnormalities directly from the CSF without requiring biopsies.
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